She fills the vacancy created this past summer, when Margie McGlynn, Ph.D. steppeed down from this post -- surprisingly, prior to the bust-up, styled as a reverse merger closing date. [Margie McGlynn herself has since landed softly, taking a seat on the board of directors of Amicus.]
This -- on balance -- looks to be a good thing for Merck's shareholders. Perhaps more importantly, from a global perspective -- she also said she would work to expand "access" to Merck's vaccines -- and that is good for all stakeholders, per Reuters reporting:
. . . .She had led the agency from one crisis to another, including the investigation into the anthrax attacks that killed five people in 2001, the H5N1 avian influenza, the global outbreak of severe acute respiratory syndrome, or SARS, and various outbreaks of food poisoning.
"As a preeminent authority in public health, infectious diseases and vaccines, Dr. Gerberding is the ideal choice to lead Merck's engagement with organizations around the world that share our commitment to the use of vaccines to prevent disease and save lives," Merck Chief Executive Officer Richard Clark said in a statement.
"I am very excited to be joining Merck where I can help to expand access to vaccines around the world," added Gerberding, who will head up the company's $5 billion global vaccine business. . . .
Here's to hopin'. . .
2 comments:
Is Margie McGlynn a Dr? I am pretty sure she isn't. It is notable that she is being replaced by one. This is not a research or scientific position; she will be heading a business unit that sells vaccines.
I think McGlynn is a Ph.D.
Thanks! -- I've edited the copy accordingly.
Namaste
Post a Comment